BillionToOneBLLN +2.04%13 PB Ratio is 11.12 as of Jul. 01, 2026, which is 36% above its 10-year median of 8.15. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, BillionToOne ranks worse than 89.23% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-01), BillionToOne's share price is $122.33. BillionToOne's Book Value per Share for the quarter that ended in Mar. 2026 was $11.00. Hence, BillionToOne's PB Ratio of today is 11.12.
Warning Sign:
BillionToOne Inc stock PB Ratio (=10.9) is close to 1-year high of 10.9.
The historical rank and industry rank for BillionToOne's PB Ratio or its related term are showing as below:
BLLN'
s PB Ratio Range Over the Past 10 Years
Min: 6.59 Med: 8.15 Max: 11.36
Current: 11.12
During the past 3 years, BillionToOne's highest PB Ratio was 11.36. The lowest was 6.59. And the median was 8.15.
BLLN's PB Ratio is ranked worse than 89.23% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.02
vs BLLN: 11.12
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BillionToOne PB Ratio Related Terms
BillionToOne PB Ratio Historical Data
* Premium members only.
The historical data trend for BillionToOne's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's PB Ratio distribution charts can be found below:
* The bar in red indicates where BillionToOne's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
BillionToOne's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BillionToOne (BLLN) has a PB Ratio of 11.12 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BillionToOne and its competitors. This is 36% above median its historical median of 8.15. Over the past decade, BillionToOne's PB Ratio has ranged from 6.59 to 11.36. According to the industry distribution chart, BillionToOne ranks #174 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 89.2%.
Is BillionToOne's PB Ratio too high?
BillionToOne's current PB Ratio of 11.12 is 36% above median its 10-year median of 8.15. Over the past 10 years, this metric has ranged from a low of 6.59 to a high of 11.36. The Medical Diagnostics & Research industry median PB Ratio is 2.02. BillionToOne's value of 11.12 is 450.5% above this industry median. Based on the distribution chart, BillionToOne ranks #174 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's PB Ratio compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #174 out of 195 companies for PB Ratio. This places BillionToOne in the lower half of its industry. The industry median PB Ratio is 2.02. BillionToOne's value of 11.12 is 450.5% above this benchmark. Historically, BillionToOne's own PB Ratio has ranged from 6.59 to 11.36 over the past decade. While the company's 10-year median is 8.15 vs. the industry median of 2.02, BillionToOne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.02, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current PB Ratio of 11.12 is 450.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current PB Ratio is 11.12, which is 36% above median its own 10-year median of 8.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current PB Ratio of 11.12. The current PB Ratio is 11.12, which is 36% above median its 10-year median of 8.15 and 450.5% above the Medical Diagnostics & Research industry median of 2.02. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BillionToOne (BLLN), the current PB Ratio is 11.12 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 